“Asian Phyto Suicols” penetrates the business with Killer T Cells, continues to expand the base of HIV cancer products through online channels. Set up a pet food supplement business Set a sales target of 10 million baht. Prepare to export Taiwan and America. Launched the Apco Health Ambassador Program To drive the operating results of the year 65 to grow not less than 50%, maintain a gross profit margin of not less than 80%
Prof. Dr. Pichet Wiriyachitra, Chief Executive Officer of Asian Phyto Naturals Public Company Limited or APCO, the owner of natural innovations for health and beauty through research, development, production and distribution of a full range of products revealed that From the experience of stimulating killer T Cells with edible plant extracts It was the principle for developing the world’s first undetectable immunotherapy regimen for HIV-positive people and for patients with cancer of all parts of the body. Handled more than 2,000 problems
Latest technology can be used to extract and improve the immunotherapy formula. To increase the number of Killer T Cells to a level suitable for use as immunotherapy for each type of disease, APCO has therefore focused on the use of Killer T Cells in its business expansion as follows:
1. Establish KILLER T CELL CO.,LTD. for those interested in applying this innovation to use in Wellness Centers for distribution both in Thailand and abroad. For use in the prevention and treatment of viral, fungal, bacterial infections. and cancer symptoms at all stages
2. Establish a Killer T Cell Therapy for HIV Center with medical institutions in Thailand. Service for infected people from around the world to receive services in Thailand. and/or use the Remote Monitoring online communication system in the same way as Telemedicine, providing services to those who cannot travel to receive services in Thailand. An MOU is now being signed with Eco Green Concept to bring approximately 200 foreign infected people into the center a month for treatment, beginning in 2Q22.
3. Established KILLER T CELL FOR PETS CO.,LTD. with specialist veterinarians. To use innovative immune therapy with Killer T Cells to treat pets with cancer, fungal infections, bacteria, AIDS and other viruses. that does not yet have a cure Distributed widely both in Thailand and abroad. The goal is to have a turnover of 10 million baht in Thailand in 2022 and prepare to sell to Taiwan and America in late 2022 or early 2023.
For businesses that are already in operation The company plans to expand its market with the success of its HIV immunotherapy, which has already been announced as the world’s first success. in making the infected person undetectable without the use of antiviral drugs and have continued good health It is expected that sales from this innovation will increase by 50% from last year.
section on cancer immunotherapy The company aims to conduct comprehensive online marketing. including opening an online patient counseling center by the Faculty of Medical Sciences which consists of medical professional Scientists and pharmacists every week expect to continue to increase sales from this innovation.
At the same time, innovation formula of culture which causes aging, anti-aging, and longevity and good health. Apco Health Ambassador (AHA : APCO Health Ambassador) introduces innovations to those who love and wish well. Along with giving a reward of approximately 2,000,000 baht for health ambassadors who can refer 1,000 consumers, this method will quickly reach 20,000 continuous consumers. If the project is successful Expected to result in a 3x increase in earnings
Business operations in foreign countries The company continues to monitor and support its partners to continually increase sales in China. and began to support licensed partners in Indonesia to further increase sales of immunization products faster in the face of the COVID-19 pandemic. eased and facilitated transportation of goods
However, if the aforementioned operation has been successful as planned The Company’s operating results in 2022 are expected to grow at least 50% and maintain a gross profit margin of at least 80%.
